Therapeutic Response

v::RET status confers therapeutic sensitivity to Selpercatinib in patients with Anaplastic Thyroid Cancer.

Statements

Source and description

Retevmo (selpercatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted accelerated approval to selpercatinib for the treatment of treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).